Editorial Comment to Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision

Affiliations

Editorial

Hajime Tanaka. Int J Urol. 2020 Sep.

. 2020 Sep;27(9):710.

doi: 10.1111/iju.14314. Epub 2020 Jul 21.

No abstract available

Comment on

Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision.
Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Matsumoto H, et al. Int J Urol. 2020 Sep;27(9):702-709. doi: 10.1111/iju.14281. Epub 2020 Jun 21. Int J Urol. 2020. PMID: 32564429

1. Matsumoto H, Shiraishi K, Azuma H et al. Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: summary of the revision. Int. J. Urol. 2020; https://doi.org/10.1111/iju.14281.
1. Burger M, Grossman HB, Droller M et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 2013; 64: 846-54.
1. Geavlete B, Multescu R, Georgescu D et al. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)? BJU Int. 2012; 109: 549-56.
1. Parekh DJ, Reis IM, Castle EP et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018; 391: 2525-36.
1. Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 2017; 376: 1015-26.